134 related articles for article (PubMed ID: 7549896)
21. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
22. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
23. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
24. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
26. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
27. DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
Lotito L; Ferri F; Russo A; Capranico G
Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653
[TBL] [Abstract][Full Text] [Related]
28. Effect of protease inhibitors on early events of apoptosis.
Hara S; Halicka HD; Bruno S; Gong J; Traganos F; Darzynkiewicz Z
Exp Cell Res; 1996 Mar; 223(2):372-84. PubMed ID: 8601414
[TBL] [Abstract][Full Text] [Related]
29. A model for tumor cell killing by topoisomerase poisons.
Zhang H; D'Arpa P; Liu LF
Cancer Cells; 1990 Jan; 2(1):23-7. PubMed ID: 2167111
[TBL] [Abstract][Full Text] [Related]
30. Catalytic function of DNA topoisomerase II.
Osheroff N; Zechiedrich EL; Gale KC
Bioessays; 1991 Jun; 13(6):269-73. PubMed ID: 1654050
[TBL] [Abstract][Full Text] [Related]
31. [Mechanism of occurrence of secondary tumors by antitumor drugs].
Andoh T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):1988-98. PubMed ID: 10584562
[TBL] [Abstract][Full Text] [Related]
32. [DNA topoisomerase inhibitor].
Hino M; Niitani H
Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
[TBL] [Abstract][Full Text] [Related]
33. Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks.
Senarisoy M; Canturk P; Zencir S; Baran Y; Topcu Z
Cell Biochem Biophys; 2013 May; 66(1):199-204. PubMed ID: 23161103
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase I and II as targets for rational design of new anticancer drugs.
Cummings J; Smyth JF
Ann Oncol; 1993 Aug; 4(7):533-43. PubMed ID: 8395870
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell death induced by topoisomerase-targeting drugs.
Li TK; Liu LF
Annu Rev Pharmacol Toxicol; 2001; 41():53-77. PubMed ID: 11264450
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase II and leukemia.
Pendleton M; Lindsey RH; Felix CA; Grimwade D; Osheroff N
Ann N Y Acad Sci; 2014 Mar; 1310(1):98-110. PubMed ID: 24495080
[TBL] [Abstract][Full Text] [Related]
37. Potency of inhibition of human DNA topoisomerase I by flavones assessed through physicochemical parameters.
Bensasson RV; Zoete V; Jossang A; Bodo B; Arimondo PB; Land EJ
Free Radic Biol Med; 2011 Oct; 51(7):1406-10. PubMed ID: 21745563
[TBL] [Abstract][Full Text] [Related]
38. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
Gatto B; Capranico G; Palumbo M
Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
[TBL] [Abstract][Full Text] [Related]
39. Topoisomerase-targeting antitumor drugs.
D'Arpa P; Liu LF
Biochim Biophys Acta; 1989 Dec; 989(2):163-77. PubMed ID: 2557085
[TBL] [Abstract][Full Text] [Related]
40. [Mechanism of action of antineoplastic agents in the DNA synthesis of tumor cells].
Nakamura T; Uchida M
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1003-10. PubMed ID: 3291763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
